Cardiac dysrhythmias

2021 ◽  
pp. 100-107
Author(s):  
Christian C. Knutsen ◽  
Donald M. Yealy
Keyword(s):  
1991 ◽  
Vol 72 (2) ◽  
pp. 273-274
Author(s):  
James R. Zaidan
Keyword(s):  

1998 ◽  
Vol 32 (6) ◽  
pp. 648-651 ◽  
Author(s):  
Vanessa Seals Gray

OBJECTIVE: To report a case of QT prolongation and syncopal episodes resulting from concomitant use of cisapride and agents known to inhibit its metabolism. CASE SUMMARY: A 53-year-old white woman was involved in two motor vehicle accidents on the same day after experiencing syncopal episodes. Cardiac and neurologic evaluations were negative; the syncopal episodes were attributed to QT prolongation associated with the concomitant use of cisapride and agents known to inhibit its metabolism. DISCUSSION: This is the first case published in the English-language literature describing QT prolongation resulting from the concomitant use of cisapride and agents known to inhibit its metabolism. Clarithromycin inhibits CYP3A4, the isoenzyme responsible for the metabolism of cisapride. Concomitant administration of cisapride with agents known to inhibit CYP3A4 (i.e., azole antifungals, erythromycin, clarithromycin) may result in elevated cisapride concentrations. Elevated cisapride concentrations have been associated with QT prolongation, syncopal episodes, and cardiac dysrhythmias. CONCLUSIONS: Acquired QT prolongation is a well-recognized adverse effect of several drugs. Recognition of newer drugs and drug combinations that place patients at risk for this potentially fatal adverse event is imperative for appropriate monitoring and prevention.


Author(s):  
D. J. Rowlands ◽  
W. C. Brownlee
Keyword(s):  

2016 ◽  
Vol 65 (45) ◽  
pp. 1276-1277 ◽  
Author(s):  
William Eggleston ◽  
Jeanna M Marraffa ◽  
Christine M Stork ◽  
Maria Mercurio-Zappala ◽  
Mark K Su ◽  
...  

2017 ◽  
Vol 221 (02) ◽  
pp. 67-72 ◽  
Author(s):  
Shi-Min Yuan

AbstractCardiac etiologies of hydrops fetalis have been a topic of concern due to challenging perinatal management. The common cardiac etiologies leading to hydrops fetalis include structural cardiac anomalies, cardiac dysrhythmias, cardiac tumors, cardiomyopathy and myocarditis. The mechanisms of cardiogenic hydrops fetalis may be: 1) elevation of atrial pressure and volume overload, 2) decrease of cardiac output, and 3) development of congestive heart failure. The diagnosis of hydrops fetalis was usually made at 19–36 gestational weeks, when ultrasound is a highly effective diagnostic method. Intrauterine interventions for certain congenital heart defects, maternal transplacental or direct fetal medications and fetal pacing placement for cardiac arrhythmias, and fetal or postnatal tumor resections are important progressions of etiologic treatment for hydrops fetalis. Treatment strategies for hydrops fetalis per se are usually ultrasound-guided pericardiocentesis and feto-amniotic shunting, whereas reaccumulation may require further interventions in utero or postnatally. Hydrops fetalis often carries a poor prognosis, and mortality remains high. Current developments in the management of hydrops fetalis should encourage physicians to attempt further fetal interventions.


1970 ◽  
Vol 42 (11) ◽  
pp. 1005-1012 ◽  
Author(s):  
G. BRICHARD ◽  
PAULETTE E. ZIMMERMANN
Keyword(s):  

1993 ◽  
Vol 13 (3) ◽  
pp. 40-46 ◽  
Author(s):  
M Schactman ◽  
J Greene

Many factors contribute to cardiac dysrhythmias in patients with pulmonary disease. The treatments themselves, as well as the clinical state of hypoxemia, can produce rhythm disturbances. A thorough understanding and awareness of the causes and treatments of the dysrhythmias of this patient population will guide the nurse in the delivery of care.


Sign in / Sign up

Export Citation Format

Share Document